Proteasome stress leads to APP axonal transport defects by promoting its amyloidogenic processing in lysosomes

Alzheimer disease (AD) pathology includes the accumulation of poly-ubiquitylated (also known as poly-ubiquitinated) proteins and failures in proteasome-dependent degradation. Whereas the distribution of proteasomes and its role in synaptic function have been studied, whether proteasome activity regu...

ver descrição completa

Detalhes bibliográficos
Autores: Otero, Maria Gabriela, Fernández Bessone, Iván, Hallberg, Alan Earle, Cromberg, Lucas Eneas, de Rossi, María Cecilia, Saez, Trinidad María de Los Milagros, Levi, Valeria, Almenar Queralt, Angels, Falzone, Tomas Luis
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2018
País:Argentina
Recursos:Consejo Nacional de Investigaciones Científicas y Técnicas
Repositório:CONICET Digital (CONICET)
Idioma:inglês
OAI Identifier:oai:ri.conicet.gov.ar:11336/90474
Acesso em linha:http://hdl.handle.net/11336/90474
Access Level:Acceso aberto
Palavra-chave:AMYLOID PRECURSOR PROTEIN
AXONAL TRANSPORT
LYSOSOME
PROTEASOME
ALZHEIMER DISEASE
https://purl.org/becyt/ford/1.6
https://purl.org/becyt/ford/1
Descrição
Resumo:Alzheimer disease (AD) pathology includes the accumulation of poly-ubiquitylated (also known as poly-ubiquitinated) proteins and failures in proteasome-dependent degradation. Whereas the distribution of proteasomes and its role in synaptic function have been studied, whether proteasome activity regulates the axonal transport and metabolism of the amyloid precursor protein (APP), remains elusive. By using live imaging in primary hippocampal neurons, we showed that proteasome inhibition rapidly and severely impairs the axonal transport of APP. Fluorescence cross-correlation analyses and membrane internalization blockage experiments showed that plasma membrane APP does not contribute to transport defects. Moreover, by western blotting and double-color APP imaging, we demonstrated that proteasome inhibition precludes APP axonal transport by enhancing its endo-lysosomal delivery, where β-cleavage is induced. Taken together, we found that proteasomes control the distal transport of APP and can re-distribute Golgi-derived vesicles to the endo-lysosomal pathway. This crosstalk between proteasomes and lysosomes regulates the intracellular APP dynamics, and defects in proteasome activity can be considered a contributing factor that leads to abnormal APP metabolism in AD.This article has an associated First Person interview with the first author of the paper.